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BACKGROUND: The purpose of this study was to assess whether analyses of tumor markers in cytological fluid can improve
the performance of computed tomography (CT)-guided needle aspiration biopsy (NAB) for the diagnosis of ground-glass
opacity (GGO) pulmonary lesions. METHODS: Forty-two patients were prospectively enrolled for CT-guided NAB. Levels
of cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) from serum and cytological fluid were
measured. The cutoff values of 3.3 ng/mL for CYFRA 21-1 and 5.0 ng/mL for CEA (threshold A) or thresholds by adding 2
standard deviations to the mean levels of markers found in patients without malignancy (threshold B) were used to
identify malignancy. The sensitivity and area under the curve (AUC) of NAB alone were compared with those of NAB com-
bined with serum or cytological tumor markers. RESULTS: Among the 42 patients, 30 (71.4%) had malignant and 12
(28.6%) had benign lesions. For NAB alone, the sensitivity, specificity, and AUC for diagnosing GGO were 70.0%, 100%,
and 0.850, respectively. The sensitivity and AUC increased significantly for NAB with cytological CYFRA 21-1 compared with
NAB alone, using both thresholds (threshold A: 86.7%, P¼.026 and .933, P¼.016; threshold B: 93.3%, P¼.008 and .925, P¼.046).
CONCLUSIONS: Cytological fluid measurements of CYFRA 21-1 can improve the diagnostic performance of CT-guided
NAB for GGO pulmonary lesions. Cancer (Cancer Cytopathol) 2013;121:214-22.VC 2012 American Cancer Society.
KEY WORDS: cytokeratin 19 fragments, CYFRA 21-1, carcinoembryonic antigen, cytological fluid, computed tomography–
guided needle aspiration biopsy, ground-glass opacity.
Recently, the diagnosis and treatment of ground-glass opacity (GGO) lesions have become important
issues, because subsolid nodules including GGO are now known to frequently represent the histologic
spectrum of lung adenocarcinoma.1 Although GGO had traditionally been regarded as areas of inflamma-
tion, hemorrhage, or fibrosis, GGO lesions appearing on computed tomography (CT) have been reported
to comprise a wide range of diagnoses, from preinvasive lesions, such as atypical adenomatous hyperplasia
or adenocarcinoma in situ, to invasive lesions, such as minimally invasive adenocarcinoma or invasive ade-
nocarcinoma.2-7 Moreover, some reports have suggested that focal GGO lesions with solid components
(mixed GGO) are significantly more likely to be associated with malignancy, especially with an invasive
component.8,9
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Currently, CT-guided percutaneous needle aspira-
tion biopsy (NAB) of the lung is the most commonly used
method for the cytologic diagnosis of pulmonary lesions.3
However, the diagnostic yield of CT-guided NAB for
GGO lesions was reported to be significantly lower than
that of solid lesions, because of the low cellularity in
GGO lesions.4 Concerning persistent GGO lesions, it
remains uncertain whether further confirmation by repeat
biopsy or surgical biopsy should be considered in cases of
inconclusive or negative results by NAB.
Serum tumor markers have been extensively studied
in lung cancer, but none are specific for detecting lung
cancer.5,6 Among several possible types of samples for tu-
mor marker analysis, cytological fluid (cell suspension of
aspirates) obtained from NAB is obtained directly from
tumor tissue and thus, candidate biomarkers may be pres-
ent in high concentrations. We performed an initial study
on cytological tumor markers which suggested that addi-
tional evaluation of the markers cytokeratin 19 fragments
(CYFRA 21-1), carcinoembryonic antigen (CEA), and
squamous cell carcinoma (SCC) antigen would be valua-
ble in improving sensitivity in diagnosis of non–small cell
lung cancer in patients undergoing NAB.10 Therefore, we
hypothesized that cytological tumor marker analysis could
also improve diagnostic performance of CT-guided NAB
for GGO lesions. This study was conducted to prospec-
tively assess whether analyses of the tumor markers
CYFRA 21-1 and CEA in cytological fluid can improve
the diagnostic performance of CT-guided NAB for GGO
pulmonary lesions.
MATERIALS AND METHODS
Study Population
This single-center prospective study was approved by our
institutional review board. Informed consent was
obtained from all subjects prior to the procedure.
Patients in whom focal GGO was detected at initial
CT scan were re-evaluated with a thin-section CT within
a 3-month interval. From October 1, 2009, to May 31,
2010, 50 patients with persistent GGO lesions suspicious
for malignancy on CT were prospectively enrolled in our
study. GGO lesions were identified by the consensus of 2
experienced chest radiologists, using thin-section CT.
GGO was defined as an area of increased attenuation
without obscuration of the underlying vessels or bronchi.7
The inclusion criteria were as follows: lesions with a GGO
component of more than 50%, patient age greater than
20 years, lesion size larger than 8 mm, and persistence or
growth of the established lesion within a 3-month pe-
riod.1,2,11,12 The exclusion criteria were indeterminate
results (n¼ 4) or refusal to provide written informed con-
sent (n¼ 4). A total of 42 patients (21 men and 21
women; mean age, 60.3 years; range, 37-79 years) with
histologically- and/or cytologically-confirmed results
were included in our final study population. Data includ-
ing sex, age, size and location of the lesion, history, results
of NAB and pathology, and laboratory data (serum and
cytological fluid tumor markers for CYFRA 21-1 and
CEA) were collected for each patient.
CT-Guided NAB and Tumor Marker Analysis
The study protocol, including the biopsy procedures and
all equipment or experimental arrangements associated
with CT-guided NABs and tumor marker analysis in
blood or cytological fluid, was performed as described.10
The biopsy procedures were performed by 3 experi-
enced chest radiologists who had 4, 6, and 10 years of
experience performing thoracic biopsies, respectively.
CT-guided NABs were performed using a 16-row multi-
detector CT scanner (Somatom Sensation 16; Siemens
Healthcare, Erlangen, Germany) equipped with CARE
Vision software (Siemens). The exposure parameters were
120 kV, 30 mAs, and slice thickness of 6 mm. During
each procedure, more than 2 aspiration specimens were
obtained using 20- to 22-gauge Chiba needles connected
to a 10-mL syringe without additional needle punctures.
Part of each aspirate was placed onto glass slides and
smeared for cytological examination and part of the mate-
rial was prepared in a tube for processing as a cell block.
All smears were immediately placed in 95% ethanol for
Papanicolaou staining. Remaining aspirates (12 mL)
were rinsed with 1 mL of normal saline solution in a tube
for the evaluation of cytological tumor markers.
In our institution, cytological results were evaluated
and divided into the following diagnostic categories: ‘‘ma-
lignant,’’ ‘‘negative for malignancy,’’ and ‘‘nondiagnostic’’
(eg, cell paucity or samples with few atypical cells). A des-
ignation of ‘‘malignancy’’ was considered a positive result.
A designation of ‘‘negative for malignancy’’ was consid-
ered a negative result. Nondiagnostic designations (n¼ 4)
Cytological Tumor Markers for Diagnosis of GGO/Kim et al
Cancer Cytopathology April 2013 215
were considered neither positive nor negative, and the
results were excluded from our study.
Blood and cytological fluid were collected from each
patient prior to therapy. Serum and cytological fluid
supernatants were obtained by centrifugation at 2000g for
10 minutes and stored at40C prior to assays for tumor
markers using commercial immunoassay kits. CYFRA
21-1 levels were measured using an electrochemilumines-
cent immunoassay (CYFRA 21-1; Roche Diagnostics,
Germany) and CEA levels were measured using a chemi-
luminescence immunoassay (Centaur CEA; Bayer
HealthCare, USA).10 Tumor markers in each cytological
fluid sample were assayed twice, with the mean values
used for analysis. Technicians performing the assays for
both serum and cytological fluid were blinded to the final
sample diagnoses.
In our study, we determined the cutoff values of the
serum and cytological tumor markers using 2 criteria.
Threshold A was defined as 3.3 ng/mL for CYFRA 21-1
and 5 ng/mL for CEA, which are the upper limits of nor-
mal serum values.13,14 Threshold B was calculated by add-
ing 2 standard deviations to the mean levels of markers
in patients without lung cancer and was defined as
5.27 ng/mL for serum CYFRA 21-1 (bCYFRA 21-1),
6.14 ng/mL for cytological CYFRA 21-1 (cCYFRA
21-1), 4.17 ng/mL for serum CEA (bCEA), and
0.31 ng/mL for cytological CEA (cCEA).15,16
Histological Analysis
The cytological specimen from the NAB was stained by
the Papanicolaou method after fixation in 95% ethanol.
The tumor tissue sampled during the operation was
imprinted on a glass slide. Tissue sections were processed
for hematoxylin and eosin stains, and histochemical
stains. Histologic classification was done according to the
proposed International Association for the Study of Lung
Cancer (IASLC)/American Thoracic Society (ATS)/Euro-
pean Respiratory Society (ERS) international multidisci-
plinary classification of lung adenocarcinoma. If there was
a disagreement in the histopathological analysis, a consen-
sus was achieved by a joint reading.
Statistical Analysis
A positive NAB result was considered a true-positive result
if there was surgical confirmation and a false-positive
result if no evidence of malignancy was found during
surgical resection in the absence of preoperative chemo-
therapy. Results were considered to be negative if no
tumor was found in the surgical specimen or disappear-
ance of the lesion was discovered on subsequent CT. If the
level of either marker was higher than its threshold, the
result was considered positive. Differences between the 2
groups (malignant and benign) were evaluated using the
chi-square test or Fisher’s exact test. Differences of serum
and cytological tumor makers among the histological sub-
groups were evaluated using the 1-way analysis of variance
or Kruskal-Wallis test. The sensitivity, specificity, accu-
racy, positive predictive value, and negative predictive
value of NAB alone and NAB combined with serum or
cytological tumor markers (CYFRA 21-1 and CEA) were
calculated. When combining NAB with tumor marker
evaluation, cases were considered positive if either NAB
or a tumor marker were positive, and were considered
negative if NAB and all tumor markers were negative.
Comparisons were made using weighted least squares to
determine the statistical significance of sensitivity and ac-
curacy between NAB combined with tumor markers and
NAB alone.17 To compare the performances of NAB
alone and NAB combined with tumor markers, receiver
operating characteristic (ROC) curves were constructed
and the areas under the curve (AUC) were compared.
Comparisons were made using the Delong method to
determine the statistical significance of AUC.18 Statistical
analyses were performed with SAS software, version 9.2
(SAS Institute, Cary, NC) and P values < .05 were con-
sidered statistically significant.
RESULTS
Our study included 42 of 50 initial patients. Among the
42 patients, 30 (71.4%) had malignant and 12 (28.6%)
had benign pulmonary lesions. Baseline characteristics of
the 42 pulmonary lesions in the malignant group, benign
group, and the total population are summarized in Table
1. There were no significant differences between the 2
groups in any of the baseline characteristics including sex,
age, lesion size, GGO component, lesion location, or past
history (P> .05) (Table 1).
All of the 30 malignant lesions were confirmed by
lobectomy. The histological types according to IASLC/
ATS/ERS classification were as follows: 23 patients with
invasive adenocarcinoma (lepidic predominant [n¼ 10],
acinar predominant [n¼ 8], papillary predominant
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[n¼ 5]), 4 patients with adenocarcinoma in situ [n¼ 4],
and 3 patients with minimally invasive adenocarci-
noma.19 Of the 30 malignant lesions, 9 were
false-negatives on NAB (lepidic predominant adenocarci-
noma [n¼ 6], adenocarcinoma in situ [n¼ 2], and mini-
mally invasive adenocarcinoma [n¼ 1]). Serum tumor
marker levels of these 9 false-negatives on NAB were lower
than the cutoff value of serum according to threshold A or
B. Of the 12 benign lesions, 6 were confirmed by surgery
such as video-assisted thoracic surgery or wedge resection,
and 6 were diagnosed as benign on the basis of subsequent
CT examinations showing complete disappearance of the
lesion (n¼ 5) or maintenance of regressed status for at
least 2 years (n¼ 1).1
The serum and cytological fluid concentrations of
CYFRA 21-1 and CEA in patients with benign and malig-
nant lesions are presented in Table 2. Serum tumor
marker levels were not significantly different between the
malignant and benign groups (P> .05). However, cCYFRA
21-1 was significantly higher in the malignant group than in
the benign group (P¼ .007). When we analyzed the serum
and cytological fluid concentrations of CYFRA 21-1 and
CEA according to histopathological subtypes, serum and
cytological tumor markers were not significantly different
among the histological subtypes (P> .05; Table 3).
Table 4 describes the sensitivity, specificity, accu-
racy, positive predictive value, and negative predictive
value of NAB alone and NAB combined with serum or
cytological tumor markers in the 42 patients. Using
threshold A, neither the sensitivity nor the accuracy were
significantly different between NAB combined with se-
rum tumor markers and NAB alone (for 2 serum tumor
markers, P> .05). However, the sensitivity and accuracy
were significantly increased for NAB combined with cCY-
FRA 21-1 compared with NAB alone. Sensitivity
increased from 70.0% with NAB alone to 86.7% when
combined with cCYFRA 21-1 (P¼ .026), and accuracy
increased from 78.6% to 90.5% (P¼ .026). However,
sensitivity and accuracy were not significantly different
between NAB combined with cCEA and NAB alone
(P¼ .084 and P¼ .084, respectively; Table 4). Using
threshold B, the sensitivity and accuracy were not signifi-
cantly different between NAB combined with serum tu-
mor markers and NAB alone (for 2 serum tumor markers,
P> .05). However, the sensitivity increased significantly
for NAB combined with cCYFRA 21-1 and cCEA com-
pared with NAB alone (93.3% for cCYFRA 21-1 and
86.7% for cCEA: P¼ .008 and P¼ .026, respectively).
Furthermore, the accuracy was significantly different
TABLE 2. Serum and Cytological Fluid Levels of
CYFRA 21-1 and CEA in 42 Patients With Malignant
and Benign Lesions
Tumor Marker
Malignant
(n 5 30)
Benign
(n 5 12) P
Serum
CYFRA 21-1 (ng/mL) 1.91  0.81 2.29  1.49 .290
CEA (ng/mL) 1.94  1.42 1.79  1.19 .742
Cytological fluid
CYFRA 21-1 (ng/mL) 30.78  52.63 2.73  1.71 .007
CEA (ng/mL) 2.70  6.58 0.18  0.07 .194
Abbreviations: CEA, carcinoembryonic antigen; CYFRA 21-1, cytokeratin 19
fragments.
Data are presented as mean  standard deviation.
TABLE 1. Demographic and Baseline Characteristics of 42 Pulmonary Lesions
Characteristic All (n 5 42) Malignant (n 5 30) Benign (n 5 12) P
Sex
Male 21 (50.0) 12 (40.0) 9 (75.0) .088
Female 21 (50.0) 18 (60.0) 3 (25.0)
Age, y
a
60.3  10.4 62.1  9.9 21.6  10.5 .087
Lesion size, mm
a
20.3  9.1 21.6  8.8 17.9  9.2 .159
Ground-glass opacity component
b (%) 50%-90% 30 (71.4) 24 (80.0) 6 (50.0) .069
>90% 12 (28.6) 6 (20.0) 6 (50.0)
Location
b
Upper/middle lobe 32 (76.2) 23 (76.7) 9 (75.0) 1.000
Lower lobe 10 (23.8) 7 (23.3) 3 (25.0)
History Smoking
b
15 (35.7) 8 (26.7) 7 (58.3) .078
Hypertension
b
13 (31.0) 10 (33.3) 3 (25.0) .722
Diabetes
b
5 (11.9) 3 (10.0) 2 (16.7) .613
Pulmonary tuberculosis
b
6 (14.3) 3 (10.0) 3 (25.0) .329
aValues in parentheses are percentages.
bFisher’s exact test.
Data are presented as mean  standard deviation.
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between NAB combined with cCYFRA 21-1 and NAB
alone (P¼ .046), but was not significantly different
between NAB combined with cCEA and NAB alone
(P¼ .103; Table 4).
For the diagnosis of malignancy using threshold A,
the AUC of NAB combined with either serum tumor
marker was not significantly larger than the AUC of NAB
alone (0.767 for bCYFRA 21-1, and 0.850 for bCEA,
both P> .05). The AUC of NAB with cCYFRA 21-1 was
significantly larger than the AUC of NAB alone (0.933
for cCYFRA 21-1 versus 0.850; P¼ .016). However, the
AUC of NAB with cCEA was not significantly larger than
the AUC of NAB alone (0.900 versus 0.850; P¼ .073;
Table 5). ROC curves of NAB alone and NAB combined
with tumor markers, using threshold A, are shown in
Figure 1. The AUC of NAB combined with either serum
tumor marker was not significantly larger than the AUC
of NAB alone for the diagnosis of malignancy, using
threshold B (0.808 for bCYFRA 21-1, and 0.808 for
bCEA, both P> .05). The AUC of NAB with cCYFRA
21-1 was significantly larger than the AUC of NAB alone
(0.925 versus 0.850; P¼ .046), whereas the AUC of NAB
with cCEA was not significantly larger than the AUC of
NAB alone (0.892 versus 0.850; P¼ .442; Table 5).
Figure 2 represents the ROC curves of NAB alone and
NAB combined with tumor markers, using threshold B.
DISCUSSION
This study was designed to examine whether analyses of
the tumor markers CYFRA 21-1 and CEA in cytological
TABLE 4. Comparison of the Diagnostic
Performances of NAB alone and NAB Combined
With Serum or Cytological Fluid Tumor Markers in
42 Patients
Diagnostic Sensitivity Specificity Accuracy PPV NPV
NAB alone 70.0 100 78.6 100 57.1
NAB þ serum tumor markers
CYFRA 21-1
Threshold A 70.0 83.3 73.8 91.3 52.6
Threshold B 70.0 91.7 76.2 95.5 55.0
CEA
Threshold A 70.0 100 78.6 100 57.1
Threshold B 70.0 91.7 76.2 95.5 55.0
NAB þ cytological fluid tumor markers
CYFRA 21-1
Threshold A 86.7 100 90.5 100 75.0
Threshold B 93.3 91.7 92.9 96.6 84.6
CEA
Threshold A 80.0 100 85.7 100 66.7
Threshold B 86.7 91.7 88.1 96.3 73.3
Abbreviations: CEA, carcinoembryonic antigen; CYFRA 21-1, cytokeratin 19
fragments; NAB, needle aspiration biopsy; NPV, negative predictive value;
PPV, positive predictive value.
Values shown are percentages. Threshold A ¼ Cutoff values of 3.3 ng/mL
and 5 ng/mL for serum or cytological fluid CYFRA 21-1 and CEA, respec-
tively; Threshold B ¼ Threshold calculated by adding 2 standard deviations
to the mean level found in patients without lung cancer.
TABLE 3. Serum and Cytological Fluid Levels of CYFRA 21-1 and CEA According to Histopathological
Subtypes
Tumor Marker
Invasive
Adenocarinoma
(n 5 23)
Minimally Invasive
Adenocarcinoma
(n 5 3)
Adenocarcinoma
In Situ (n 5 4) P
Serum (ng/mL)
CYFRA 21-1 1.83  0.82 2.41  0.77 2.01  0.81 .776
CEA 1.81  1.19 1.96  1.24 2.63  2.68 .795
Cytological fluid (ng/mL)
CYFRA 21-1 35.78  59.23 14.51  18.24 17.75  13.61 .163
CEA 2.72  7.38 2.78  4.61 2.50  2.47 .611
Tumor Marker
Lepidic Predominant
(n 5 10)
Acinar Predominant
(n 5 8)
Papillary Predominant
(n 5 5) P
Serum (ng/mL)
CYFRA 21-1 1.86  0.61 1.56  0.93 2.18  1.05 .874
CEA 1.75  1.41 1.68  1.02 2.17  1.12 .747
Cytological fluid (ng/mL)
CYFRA 21-1 42.39  63.18 16.54  16.28 32.51  43.45 .637
CEA 4.43  11.07 2.84  1.17 2.41  2.27 .643
Abbreviations: CEA, carcinoembryonic antigen; CYFRA 21-1, cytokeratin 19 fragments.
Data are presented as mean  standard deviation.
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fluid could improve the performance of CT-guided NAB
in the diagnosis of persistent GGO pulmonary lesions.
We found that CT-guided NAB with additional evalua-
tion of CYFRA 21-1 can improve sensitivity and accuracy
in the diagnosis of persistent GGO pulmonary lesions.
Early detection of small malignant pulmonary nod-
ules is important because it can lead to early, potentially
curative treatment.18 The improved detection of focal
GGO lesions by advanced CT screening necessitates the
definite diagnosis of GGO, although the diagnostic accu-
racy of CT-guided NAB for GGO lesions is not well
established. Despite the relative safety and accuracy of
CT-guidedNAB for the diagnosis of lung lesions, nonspe-
cific or false-negative results are common, with reported
incidences ranging from 5.5% to 29%.3,20-22 Moreover,
the diagnostic yield of CT-guided NAB for GGO lesions
is significantly lower than that of solid lesions, especially
for lesions with a GGO component > 90%.4,23 Shimizu
et al4 reported that the diagnostic yield of CT-guided
NAB was 51.2% for GGO lesions and 75.6% for solid
lesions. Therefore, the proper clinical management of per-
sistent GGO remains controversial, and patients with
suspected malignancies but inconclusive results on initial
lung biopsy often require additional transthoracic lung bi-
opsy or surgical biopsy, including video-assisted thoracic
surgery. We attempted to improve the diagnosis of GGO
lesions by using cytological fluid instead of blood serum
for tumor marker analysis. Although blood is useful for
FIGURE 1. Receiver operating characteristic (ROC) curves of needle aspiration biopsy (NAB) alone and NAB with (A) serum or
(B) cytological fluid tumor markers using threshold A with cutoff values of 3.3 ng/mL and 5 ng/mL for cytokeratin 19 fragments
(CYFRA 21-1) and carcinoembryonic antigen (CEA) levels, respectively. The solid curve, dashed curve, and dot-and-dash curve
represent NAB alone, NAB combined with CYFRA 21-1, and NAB combined with CEA, respectively.
TABLE 5. Comparison of the Diagnostic
Performance of NAB Alone and NAB With Serum
or Cytological Fluid Tumor Markers in 42 Patients
Tumor Marker AUC P
NAB alone 0.850 (0.767-0.933)
NAB þ serum tumor marker
CYFRA 21-1 Threshold A 0.767 (0.629-0.905) .138
Threshold B 0.808 (0.692-0.925) .317
CEA Threshold A 0.850 (0.767-0.933) 1.000
Threshold B 0.808 (0.692-0.925) .317
NAB þ cytological fluid tumor marker
CYFRA 21-1 Threshold A 0.933 (0.872-0.995) .016
Threshold B 0.925 (0.832-1.000) .046
CEA Threshold A 0.900 (0.827-0.973) .073
Threshold B 0.892 (0.789-0.994) .442
Abbreviations: AUC, area under the curve; CEA, carcinoembryonic antigen;
CYFRA 21-1, cytokeratin 19 fragments; NAB, needle aspiration biopsy.
Threshold A ¼ Cutoff values of 3.3 ng/mL and 5 ng/mL for serum or cytologi-
cal fluid CYFRA 21-1 and CEA, respectively; Threshold B ¼ Threshold calcu-
lated by adding 2 standard deviations to the mean level found in patients
without lung cancer. Values in parentheses are 95% confidence intervals.
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the analysis of serum biomarkers and contains a large pro-
teome that reflects health status,24-27 one of the main
drawbacks of using serum tumor markers is that these
markers are typically found in high concentrations only
near the tumor tissue or when the disease is at an advanced
stage.11,12 Therefore, it remains very difficult to use serum
marker assays to clinically detect lung tumors at early
stages.25,28 Cytological fluid might be a more effective
sample fluid than blood for the evaluation of tumor
markers, because it is obtained directly from tumor tissue,
and therefore could contain many biomarkers in high
concentrations.25 Recently, we reported that the sensitiv-
ity for diagnosing non–small cell lung cancer increased
significantly for NAB combined with cytological tumor
markers compared with NAB alone (100% for cCYFRA
21-1, 92.9% for cCEA, and 94.2% for cSCC; P¼ .001,
P¼ .025, and P¼ .014, respectively), and the AUC of
NAB with cCYFRA 21-1 was significantly larger than the
AUC of NAB alone (P¼ .001).10
According to the results of this study, the additional
evaluation of tumor markers in cytological fluid can
improve the diagnostic performance of CT-guided NAB
for GGO pulmonary lesions. Although sensitivity and ac-
curacy did not significantly differ between NAB com-
bined with any serum tumor marker and NAB alone, the
sensitivity and accuracy of diagnosis increased signifi-
cantly for NAB combined with cCYFRA 21-1 compared
with NAB alone. By calculating ROC curves, we observed
that the AUC of NAB with cCYFRA 21-1 was signifi-
cantly larger than that of NAB alone or NAB with serum
tumor markers, indicating that this cytological tumor
marker has additional value for the diagnosis of GGO
pulmonary lesions. Our results revealed that cCYFRA 21-
1 had better diagnostic performance than other tumor
markers related to lung cancer, similar to findings of pre-
vious studies concerning diagnostic performance of serum
tumors related to lung cancer.5,10,11,29
Our study had a number of limitations. First, our
sample size was relatively small, and we were therefore
unable to verify that surgery should be performed in
patients with elevated NAB tumor marker concentrations
in the absence of malignant cells found by fine-needle
aspiration cytology. Second, the benign and malignant
pathologic results were not represented in equal numbers,
because more than half of the confirmed cases were malig-
nant. Therefore, the values of cytological tumor markers
FIGURE 2. Receiver operating characteristic (ROC) curves of needle aspiration biopsy (NAB) alone and NAB with with (A) serum
or (B) cytological fluid tumor markers using threshold B calculated by adding 2 standard deviations to the mean levels found in
patients without lung cancer. Each solid curve, dashed curve, and dot-and-dash curve indicates NAB alone, NAB combined with
cytokeratin 19 fragments (CYFRA 21-1), and NAB combined with carcinoembryonic antigen (CEA), respectively.
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shown in this study may be limited in malignant lesions.
Third, whereas most lesions had histopathologically-con-
firmed diagnoses, 6 benign lesions required follow-up
imaging studies and clinical examinations. Fourth, the
results of this study may be influenced by the methods
used to choose the cutoff points for cytological tumor
markers. To the best of our knowledge, no other studies on
the measurement of cytological tumor markers in patients
with GGO pulmonary lesions have been published, and
therefore, there are no established reference values for nor-
mal cytological fluid levels of various tumor markers. In
our study, we used 2 sets of reference values for cytological
fluid levels of tumor markers, including a threshold that
was calculated by adding 2 standard deviations to the mean
levels found in patients without lung cancer and another
threshold that observed lower cutoff values of 3.3 ng/mL
and 5 ng/mL for CYFRA 21-1 and CEA, respectively.
Measurement of the tumor marker CYFRA 21-1 in
cytological fluid can improve the diagnostic performance
of CT-guided NAB for persistent GGO pulmonary
lesions. On the basis of our results, cytological fluid appears
to be suitable for assessing the presence and concentrations
of tumor markers that might be clinically helpful to make
definite diagnoses of GGO lesions. The ability to make a
definite diagnosis is particularly important, because
although lung biopsy using needle aspiration can confirm
the diagnosis of lung cancer, the diagnostic yield and sensi-
tivity of NAB for GGO pulmonary lesions are significantly
lower than for solid pulmonary nodules because of the
lower cellularity of GGO lesions.4,23 Performing the extra
step of tumor marker concentration measurement in aspi-
rated cytological fluid takes additional time for analysis and
increases cost for these assays. However, it does not require
additional puncture and is relatively easy. Considering that
the AUC of NAB with cCYFRA 21-1 was significantly
larger than that of NAB alone or NAB with any serum tu-
mor markers, the clinical benefit of adding cytological fluid
analysis for diagnosing persistent GGO lesions is evident.
Therefore, we believe that our results provide a rationale
for the evaluation of tumor markers in cytological fluid
that is complementary to conventional means of diagnosis
of persistent GGO pulmonary lesions.
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